GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (NAS:ORGS) » Definitions » Cyclically Adjusted Price-to-FCF

Orgenesis (Orgenesis) Cyclically Adjusted Price-to-FCF : (As of Apr. 29, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Orgenesis Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Orgenesis Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Orgenesis's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis Cyclically Adjusted Price-to-FCF Chart

Orgenesis Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Orgenesis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Orgenesis's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Orgenesis's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orgenesis's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orgenesis's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Orgenesis's Cyclically Adjusted Price-to-FCF falls into.



Orgenesis Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Orgenesis's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Orgenesis's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.016/129.4194*129.4194
=-0.016

Current CPI (Dec. 2023) = 129.4194.

Orgenesis Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201402 -0.115 99.057 -0.150
201405 -0.094 100.373 -0.121
201408 -0.039 100.352 -0.050
201411 -0.069 99.635 -0.090
201502 -0.138 99.032 -0.180
201505 -0.117 100.333 -0.151
201508 -0.273 100.548 -0.351
201511 -0.245 100.135 -0.317
201602 -0.197 100.040 -0.255
201605 -0.132 101.355 -0.169
201608 -0.146 101.617 -0.186
201611 -0.143 101.829 -0.182
201702 0.016 102.779 0.020
201705 -0.250 103.256 -0.313
201708 -0.176 103.587 -0.220
201711 -0.071 104.072 -0.088
201802 -0.245 105.052 -0.302
201805 -0.525 106.148 -0.640
201808 -0.513 106.383 -0.624
201811 -0.286 106.338 -0.348
201903 -0.356 107.251 -0.430
201906 -0.339 108.070 -0.406
201909 -0.353 108.329 -0.422
201912 -0.543 108.420 -0.648
202003 -0.809 108.902 -0.961
202006 -0.438 108.767 -0.521
202009 -0.466 109.815 -0.549
202012 -1.904 109.897 -2.242
202103 -0.210 111.754 -0.243
202106 -0.514 114.631 -0.580
202109 -0.419 115.734 -0.469
202112 -0.287 117.630 -0.316
202203 -0.150 121.301 -0.160
202206 -0.397 125.017 -0.411
202209 -0.298 125.227 -0.308
202212 -0.634 125.222 -0.655
202303 -0.322 127.348 -0.327
202306 -0.227 128.729 -0.228
202309 -0.051 129.860 -0.051
202312 -0.016 129.419 -0.016

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Orgenesis  (NAS:ORGS) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Orgenesis Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Orgenesis's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Orgenesis (Orgenesis) Business Description

Industry
Traded in Other Exchanges
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Morgenesis and Therapies.
Executives
Elliot Maltz officer: Chief Financial Officer C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116
Jacob Safier 10 percent owner C/O THE WOLFSON GROUP, ONE STATE STREET PLAZA 29TH FLOOR, NEW YORK NY 10004
Efrat Assa Kunik officer: Chief Development Officer C/O ORGENESIS INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
David Sidransky director JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205
Mario Philips director C/O ATMI, INC, DANBURY CT 06810
Sarah Ferber officer: Chief Scientific Officer 17B HAHASKALA STREET, TEL AVIV L3 67890
Guy Yachin director 7 ORCHARD WAY N, POTOMAC MD 20854
Yaron Adler director 4 HA'NECHOSHET ST., RAMAT HA'CHAYAL, TEL AVIV L3 69710
Vered Caplan officer: CEO 20 HA'ETZEL STREET, PO BOX 9118 RAMAT EFAL, KIRYAT ONO L3 55280
Universite Libre De Bruxelles 10 percent owner AVENUE F, ROOSEVELT, 50, BRUSSELS C9 1050
Olivier Belenger 10 percent owner DIEWEG, 69, BRUSSELS C9 1070
Ii Sa Theodorus 10 percent owner ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Sca Theodorus 10 percent owner ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Denis Bedoret officer: See Remarks 48, RUE AUGUSTE PICCARD, GOSSELIES C9 6041
Ashish Nanda director 2301, 23RD FLOOR, TIFFANY TOWERS, CLUSTER W, JLT, DUBAI, UAE, DUBAI C0 4452